无毛小鼠白癜风模型:提升临床前治疗评估
本研究利用无毛hk14-SCF Tg小鼠建立白癜风模型,其黑素细胞分布接近人皮肤。通过gp100肽脉冲树突状细胞联合PMEL CD8+ T细胞诱导,或与PMEL TCR转基因小鼠杂交,模型机制与既往模型及患者相似。UV、外用糖皮质激素和Jak抑制剂均显著减少白斑面积。
要点
- 无毛hk14-SCF Tg小鼠黑素细胞分布接近人皮肤,便于客观评估疗效。
- 两种诱导方法均复制出与既往模型及患者相似的白癜风机制。
- UV、外用糖皮质激素和Jak抑制剂均显著减少白斑面积。
核心结论
- 该无毛小鼠白癜风模型克服既往模型局限,为临床前治疗评估提供稳健平台。
研究设计与样本
- 使用无毛hk14-SCF Tg小鼠,采用gp100肽脉冲骨髓来源树突状细胞联合靶向gp100的PMEL CD8+ T细胞诱导白癜风。
- 或将hk14-SCF Tg小鼠与PMEL TCR转基因小鼠杂交,无需额外处理。
- 皮肤样本采用免疫组化、流式细胞术、bulk RNA测序和细胞因子检测分析。
主要发现
- 模型驱动白癜风的机制与既往小鼠模型及白癜风患者 closely 相似。
- UV照射、外用糖皮质激素和Jak抑制剂均显著减少白斑面积,经ImageJ客观分析验证。
临床怎么用
- 该模型可用于临床前评估白癜风治疗,包括UV、外用糖皮质激素和Jak抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vitiligo is an autoimmune disease that targets melanocytes, and preclinical models of the disease can strongly promote the development of new treatments. This study introduces a vitiligo model using hairless hk14-SCF Tg mice, whose melanocyte distribution closely mimics that of human skin, enabling comprehensive therapeutic evaluation. Two methods were used to induce vitiligo: (i) hairless hk14-SCF Tg mice received bone marrow-derived dendritic cells pulsed with the melanocyte-specific peptide gp100 and CD8+ T cells targeting gp100 (PMEL CD8+ T cells), and (ii) hk14-SCF Tg mice were crossbred with PMEL TCR transgenic mice without additional treatment. Skin samples were subsequently analyzed using immunohistochemistry, flow cytometry, bulk RNA sequencing, and cytokine assays, confirming that the mechanisms that drive vitiligo in this model closely resemble those of prior mouse models and patients with vitiligo. Various treatments, including UV irradiation, topical corticosteroids, and a Jak inhibitor, were tested, and all significantly reduced vitiligo-affected areas, as verified through objective ImageJ analysis. In conclusion, this model addresses key limitations of previous models, offering a robust platform for preclinical treatment evaluation and potentially accelerating clinical translation.
引用
- Okamura K, Arai Y, Kawaguchi J, et al. A Hairless Mouse Model for Vitiligo: Enhancing Preclinical Therapeutic Evaluation. J Invest Dermatol. 2025. PMID: 40701402. doi:10.1016/j.jid.2025.06.1596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。